The Ozempic lawsuit 2026 is shaping up to be the biggest year yet for thousands of plaintiffs who say this popular diabetes drug caused them serious harm. Bellwether trials are on the horizon, settlement talks are heating up, and the window to file a claim is shrinking.
If you took Ozempic and suffered gastroparesis, bowel obstruction, or other severe stomach problems, this is the year that matters most. More than 16,000 claims have been filed in the federal multidistrict litigation as of early 2026.
This article breaks down every major development. You'll find settlement projections, eligibility rules, filing deadlines, MDL court progress, and payout estimates per person.
Whether you're already part of the lawsuit or just starting to look into it, everything you need to know is right here.
Ozempic Lawsuit 2026: What You Need to Know Right Now
The Ozempic lawsuit in 2026 is a mass tort action against Novo Nordisk, the pharmaceutical company that manufactures semaglutide-based drugs. Plaintiffs allege the company knew about severe gastrointestinal risks and failed to properly warn patients or doctors.
The litigation is centralized in federal court under MDL No. 3094 in the Eastern District of Pennsylvania. This is where all federal Ozempic, Wegovy, and related GLP-1 drug claims are being coordinated.
Here's a snapshot of where things stand right now:
| Detail | Info |
|---|---|
| MDL Number | 3094 |
| Court | Eastern District of Pennsylvania |
| Defendant | Novo Nordisk |
| Total Claims Filed | 16,000+ (as of early 2026) |
| Key Injuries | Gastroparesis, bowel obstruction, pancreatitis |
| Status | Discovery phase, bellwether selection underway |
The case has grown faster than most pharmaceutical mass torts in recent memory. New plaintiffs continue to join every month.
What makes 2026 different is the pace. The court has pushed both sides to move through discovery quickly. Early trial dates could set the tone for global settlement negotiations.
Think of bellwether trials like test drives. They let both sides see how juries react before anyone commits to a big settlement deal.
Ozempic Lawsuit Update for 2026
The most important Ozempic lawsuit update heading into 2026 is that bellwether case selection has begun. The court ordered both plaintiffs and defendants to identify a pool of representative cases for early trials.
Discovery is ongoing, which means both sides are exchanging documents, depositions, and expert reports. Novo Nordisk has produced internal communications related to safety signal detection for semaglutide products.
Key developments include:
- Bellwether pool identified: Approximately 30 to 40 cases have been shortlisted for potential early trial.
- Expert witness deadlines: Plaintiffs' expert reports on causation are due in the first half of 2026.
- Daubert hearings scheduled: The court will decide whether plaintiffs' scientific evidence meets the standard for trial.
- FDA label review: New labeling language around gastroparesis risk was added in late 2025, strengthening plaintiff arguments.
Novo Nordisk continues to deny liability. The company argues its labels provided adequate warnings about gastrointestinal side effects. But plaintiffs say the warnings were vague and buried.
The pace of this litigation is unusual. Most pharmaceutical MDLs take five to seven years to reach trial. This one is moving closer to the three-to-four-year mark.
That speed matters because faster trials mean faster settlement pressure. When a jury returns a big verdict, defendants tend to come to the table.
Ozempic Lawsuit Latest News
The latest news in the Ozempic lawsuit involves several parallel developments in both federal and state courts. At the federal level, Judge Gene E.K. Pratter has been actively managing the MDL docket to prevent delays.
In early 2026, the court issued a case management order setting firm deadlines for the remainder of the year. Those deadlines include:
- Expert discovery completion by mid-2026
- Daubert motions filed by Q3 2026
- First bellwether trial potentially scheduled for late 2026 or early 2027
On the state court side, several cases in California, Illinois, and New Jersey are proceeding independently. Some state cases are ahead of the federal MDL in terms of trial readiness.
Another major headline: the FDA's FAERS database now shows more than 100,000 adverse event reports linked to semaglutide products since 2017. That number has grown sharply as prescriptions for Ozempic and Wegovy have surged.
New scientific studies published in 2025 and early 2026 have added weight to the causation argument. Researchers at academic medical centers have found a statistically significant link between semaglutide use and delayed gastric emptying lasting months after discontinuation.
This matters because Novo Nordisk has argued that gastroparesis symptoms resolve once patients stop taking the drug. New data challenges that defense.
Key Takeaway: The Ozempic lawsuit is accelerating in 2026, with bellwether selection underway, new FDA data strengthening plaintiff claims, and trial dates coming into view for the first time.
Ozempic Lawsuit Settlement Amounts in 2026
Settlement amounts in the Ozempic lawsuit have not been finalized because no global settlement has been reached yet. However, legal analysts and mass tort attorneys have projected ranges based on similar pharmaceutical cases.
The projected settlement tiers look something like this:
| Injury Severity | Estimated Settlement Range |
|---|---|
| Tier 1: Death or permanent injury | $300,000 to $1,000,000+ |
| Tier 2: Hospitalization with surgery | $150,000 to $400,000 |
| Tier 3: Gastroparesis requiring treatment | $75,000 to $200,000 |
| Tier 4: Moderate GI injury, no surgery | $25,000 to $100,000 |
These numbers are estimates based on prior mass tort outcomes in cases like Vioxx, Zantac, and opioid litigation. Actual amounts will depend on individual case facts.
Several factors will influence the final settlement figures:
- Strength of medical records connecting Ozempic use to the specific injury
- Duration and severity of the condition
- Whether the patient required surgery such as gastric stimulator implantation
- Age and overall health of the plaintiff before taking Ozempic
No settlement fund has been established yet. That typically happens after bellwether verdicts give both sides a framework for negotiations.
If early trials produce large plaintiff verdicts, the settlement numbers could skew higher. If Novo Nordisk wins early trials, settlement values could drop.
Who Qualifies for the Ozempic Lawsuit?
You may qualify for the Ozempic lawsuit if you took Ozempic (semaglutide) and developed serious gastrointestinal injuries that were not adequately warned about on the drug's label. The core requirement is a documented medical condition linked to the medication.
Here are the basic eligibility criteria most law firms are using:
- You were prescribed Ozempic or Wegovy (semaglutide)
- You took the medication for at least 2 to 3 months
- You developed a qualifying injury such as gastroparesis, bowel obstruction, pancreatitis, or gallbladder disease
- You have medical records documenting the diagnosis
- Your injury occurred while taking the drug or shortly after stopping
People who used Ozempic "off-label" for weight loss can still qualify. The lawsuit isn't limited to diabetic patients.
A few things that would likely disqualify you:
- You had a pre-existing diagnosis of gastroparesis before taking Ozempic
- You experienced only mild, temporary nausea or stomach discomfort
- You cannot produce medical records linking your injury to semaglutide use
The strongest cases involve patients who had no prior GI history and developed severe symptoms within the first year of Ozempic use. Hospitalizations and surgeries significantly increase case value.
Ozempic Gastroparesis Lawsuit in 2026
Gastroparesis is the central injury driving the Ozempic lawsuit in 2026. This condition, sometimes called "stomach paralysis," occurs when the stomach muscles stop working properly and food doesn't move through the digestive system at a normal pace.
Semaglutide works by slowing gastric emptying as part of its mechanism for blood sugar control and appetite suppression. The problem is that for some patients, this effect becomes severe and permanent.
Symptoms of gastroparesis linked to Ozempic include:
- Severe nausea and vomiting lasting weeks or months
- Inability to eat solid food
- Dramatic, unintended weight loss beyond the drug's intended effect
- Abdominal pain and bloating
- Hospitalization for dehydration or malnutrition
Plaintiffs argue that Novo Nordisk knew the risk of gastroparesis was higher than disclosed. Internal documents reportedly show the company received adverse event reports about severe gastroparesis years before updating its label language.
The FDA added a more specific gastroparesis reference to semaglutide labeling in 2024, but plaintiffs say this came too late. By that point, millions of patients had already been prescribed the drug without adequate warning.
Some patients have needed gastric electrical stimulation devices surgically implanted to manage their condition. Others remain unable to eat normally years after stopping Ozempic.
Key Takeaway: Gastroparesis remains the most common and most serious injury alleged in the Ozempic lawsuit, and new evidence in 2026 suggests the risk was known to Novo Nordisk earlier than they publicly admitted.
Ozempic MDL 2026: Where the Case Stands in Court
The Ozempic MDL (Multidistrict Litigation) No. 3094 is the federal case consolidating all Ozempic and related GLP-1 drug injury claims. As of 2026, more than 16,000 individual cases have been transferred into this MDL.
MDL is a legal mechanism that groups similar federal lawsuits under one judge for pretrial proceedings. It keeps things efficient. Instead of 16,000 separate discovery processes, everything runs through one courtroom.
| MDL Detail | Status |
|---|---|
| MDL Number | 3094 |
| Presiding Judge | Judge Gene E.K. Pratter |
| Location | U.S. District Court, Eastern District of PA |
| Cases Consolidated | 16,000+ |
| Current Phase | Discovery and bellwether selection |
| Next Major Milestone | Daubert hearings, Q3 2026 |
The discovery phase has been intense. Plaintiffs' attorneys have obtained internal Novo Nordisk emails, safety review documents, and marketing materials. These documents are expected to play a central role at trial.
One critical issue the court will address in 2026 is the Daubert challenge. Novo Nordisk will argue that plaintiffs' expert witnesses on causation don't meet the scientific reliability standard. If the judge excludes key experts, it could weaken the entire plaintiff case.
Plaintiffs are confident their experts will survive Daubert. They point to published medical literature, FDA data, and Novo Nordisk's own clinical trial results as supporting evidence.
The judge has signaled she wants to keep this litigation on a firm schedule. That's good news for plaintiffs who want resolution sooner rather than later.
Ozempic Bellwether Trial 2026
A bellwether trial is a test case that goes to trial before a jury to help both sides gauge how similar cases might play out. The first Ozempic bellwether trials could take place in late 2026 or early 2027 depending on how Daubert hearings resolve.
The bellwether selection process works like this:
- Each side nominates a group of cases from the MDL pool
- The court narrows the list to a smaller trial-ready group
- Cases are selected to represent a range of injuries and facts
- The first 3 to 5 cases go to trial individually
These trials are not binding on every plaintiff. But they send a powerful signal. If a jury awards $10 million in a single bellwether case, Novo Nordisk will face enormous pressure to settle the remaining 16,000 claims.
If the defense wins, the opposite happens. Settlement values drop, and some weaker cases may get dismissed.
In past pharmaceutical MDLs, bellwether outcomes have been the single biggest driver of settlement negotiations. The Bard hernia mesh MDL, for example, saw defense verdicts that stalled settlement talks for years. The 3M earplug MDL saw large plaintiff verdicts that pushed a $6 billion settlement.
Both sides have strong motivations to prepare thoroughly. Expect aggressive pretrial motions throughout mid-2026 as each team positions for the best possible bellwether outcome.
Ozempic Lawsuit Payout Per Person
The payout per person in the Ozempic lawsuit will vary widely based on injury severity, medical documentation, and individual case strength. No one-size-fits-all number exists yet because the case hasn't settled.
Based on attorney projections and comparable mass tort cases, here's what individual payouts might look like:
| Case Category | Projected Payout |
|---|---|
| Fatal cases | $500,000 to $1,500,000+ |
| Severe gastroparesis with surgery | $150,000 to $500,000 |
| Hospitalized gastroparesis, no surgery | $75,000 to $200,000 |
| Bowel obstruction requiring surgery | $100,000 to $350,000 |
| Moderate GI injury, outpatient treatment | $25,000 to $100,000 |
| Pancreatitis linked to semaglutide | $50,000 to $250,000 |
Your actual payout depends on several things. How long were you on the drug? How severe was your injury? Did you need hospitalization or surgery? Do you have clear medical records connecting Ozempic to your condition?
Plaintiffs with strong documentation tend to settle at the higher end of these ranges. Those with weaker medical evidence or short-term use may receive less.
Keep in mind that attorney fees will reduce your net payout. Most mass tort attorneys work on contingency, taking 33% to 40% of the settlement amount. Court costs and case expenses are typically deducted separately.
Key Takeaway: Individual payouts in the Ozempic lawsuit could range from $25,000 for moderate injuries to well over $1 million for fatal cases, but actual numbers depend on bellwether verdicts and global settlement negotiations expected to begin in late 2026 or 2027.
Ozempic Lawsuit Deadline in 2026
The deadline to file an Ozempic lawsuit depends on your state's statute of limitations for product liability or personal injury claims. There is no single national deadline, but time is running out for many plaintiffs.
Most states give you 2 to 3 years from the date you discovered (or should have discovered) that Ozempic caused your injury. This is called the "discovery rule."
| State | Statute of Limitations |
|---|---|
| California | 2 years from discovery |
| Texas | 2 years from injury |
| New York | 3 years from injury |
| Florida | 2 years from discovery (recently changed from 4) |
| Illinois | 2 years from discovery |
| Pennsylvania | 2 years from injury |
If you were diagnosed with gastroparesis in 2024, and you live in a state with a 2-year statute, your deadline could fall in 2026. Missing this window means you lose your right to file, period.
Some states also have a "statute of repose" that sets an absolute outer deadline regardless of when you discovered the injury. In those states, the clock may have already started ticking.
The safest move is to get your case evaluated now. Even if you're unsure whether you qualify, having an attorney review your situation protects your rights before any deadline passes.
Don't assume you have plenty of time. Pharmaceutical statutes of limitations are unforgiving.
How to File an Ozempic Lawsuit
Filing an Ozempic lawsuit starts with contacting a mass tort attorney who is actively handling GLP-1 drug claims. The process is simpler than most people expect, and you don't need to pay anything upfront.
Here's the step-by-step process:
- Free case evaluation: An attorney reviews your medical history, Ozempic usage, and injuries.
- Medical record collection: The law firm gathers your prescriptions, hospital records, and diagnostic tests.
- Case filing: Your attorney files a complaint in the MDL or in your state court.
- Discovery phase: Your case joins the broader litigation. You may need to answer written questions or give a deposition.
- Resolution: Your case either settles as part of a global agreement or proceeds to individual trial.
You do not need to go to court in Pennsylvania just because the MDL is there. Most pretrial activity happens through your attorney without your physical presence.
Important things to gather before you contact an attorney:
- Prescription records showing Ozempic or Wegovy use
- Medical records documenting your diagnosis (gastroparesis, bowel obstruction, etc.)
- Hospital or ER records if you were admitted
- A timeline of when you started and stopped taking the drug
- Records of any surgeries related to your GI condition
Most mass tort attorneys charge zero upfront fees. They work on contingency, meaning they only get paid if you win or settle.
Ozempic Side Effects Lawsuit: What Injuries Are Claimed?
The Ozempic side effects lawsuit centers on severe gastrointestinal injuries that plaintiffs say were not properly disclosed by Novo Nordisk. These go far beyond the mild nausea listed on the original drug label.
The primary injuries alleged in the litigation include:
- Gastroparesis (stomach paralysis): The stomach cannot empty food at a normal rate. Can become chronic or permanent.
- Intestinal obstruction (bowel blockage): The small or large intestine becomes blocked, often requiring emergency surgery.
- Ileus: The intestines stop contracting, leading to severe constipation and abdominal distension.
- Pancreatitis: Inflammation of the pancreas causing intense abdominal pain and potentially life-threatening complications.
- Gallbladder disease: Including gallstones, cholecystitis, and gallbladder removal surgery.
- Cyclic vomiting syndrome: Repeated episodes of severe vomiting lasting hours or days.
Plaintiffs argue Novo Nordisk had data from clinical trials and post-market surveillance showing these risks were more common than the company publicly acknowledged.
The failure-to-warn theory is the backbone of most claims. It's not about whether semaglutide has side effects. Every drug has side effects. It's about whether the company told patients and doctors the truth about how serious those side effects could be.
When a drug label says "nausea" but the real risk is "your stomach may stop functioning permanently," that's a failure-to-warn problem.
Key Takeaway: The Ozempic lawsuit isn't about mild stomach upset. It targets severe, life-altering injuries like permanent gastroparesis and emergency bowel surgery that plaintiffs say Novo Nordisk hid from the public.
Is the Ozempic Lawsuit a Class Action in 2026?
The Ozempic lawsuit is not a class action. It is a mass tort handled through multidistrict litigation (MDL). The difference matters because it affects how your case is evaluated and what you might receive.
Here's a quick comparison:
| Feature | Class Action | Mass Tort (MDL) |
|---|---|---|
| Individual evaluation | No, one-size-fits-all | Yes, each case judged individually |
| Settlement amounts | Equal payout to all members | Varies by injury severity |
| Opt-in required | Usually automatic | Must actively file a claim |
| Trial process | One trial for the whole class | Bellwether trials, then settlement |
| Attorney relationship | Class counsel for everyone | Your own attorney represents you |
In a class action, everyone gets the same deal. In a mass tort, your payout is based on your specific injuries and medical evidence. That's why a person with severe gastroparesis requiring surgery might receive ten times more than someone with moderate nausea.
This distinction is a good thing for seriously injured plaintiffs. Your case isn't diluted by being lumped in with people who had milder reactions.
Each plaintiff in the MDL has their own attorney who advocates for their individual interests. Your lawyer negotiates your specific settlement based on your records, not a generic formula.
Some people call it a "class action" casually, and that's understandable. But legally, it's a different animal.
GLP-1 Lawsuit 2026: Beyond Ozempic
The GLP-1 lawsuit in 2026 extends beyond Ozempic alone. The MDL includes claims against multiple GLP-1 receptor agonist drugs, which means the litigation targets an entire class of medications.
Drugs included in or related to the MDL:
- Ozempic (semaglutide, Novo Nordisk): The most commonly named drug in the litigation.
- Wegovy (semaglutide, Novo Nordisk): Same active ingredient as Ozempic, marketed for weight loss.
- Mounjaro (tirzepatide, Eli Lilly): A newer GLP-1 drug facing similar claims.
- Rybelsus (oral semaglutide, Novo Nordisk): Oral form of the same drug.
- Trulicity (dulaglutide, Eli Lilly): An older GLP-1 drug with its own set of injury claims.
Eli Lilly faces growing legal exposure in 2026 as Mounjaro prescriptions have skyrocketed. Some attorneys project that Mounjaro claims could eventually rival Ozempic claims in number.
The broader GLP-1 litigation raises an important question: is the problem with semaglutide specifically, or with the entire GLP-1 drug class mechanism? Plaintiffs' experts argue that slowing gastric emptying to the extreme is a foreseeable risk of any GLP-1 agonist.
If that argument holds up in court, it could open the door to claims against every GLP-1 drug on the market. That would make this one of the largest pharmaceutical mass torts in U.S. history.
Watch for Eli Lilly's legal strategy in 2026. The company may try to distance Mounjaro from Ozempic by arguing tirzepatide has a different risk profile than semaglutide.
Ozempic Lawsuit Settlement Timeline
The Ozempic lawsuit settlement timeline stretches from 2026 into 2027 or even 2028, depending on how bellwether trials and Daubert hearings play out. No global settlement is expected before at least one bellwether verdict.
Here's the projected timeline:
| Milestone | Expected Date |
|---|---|
| Bellwether case pool finalized | Q1-Q2 2026 |
| Daubert hearings on expert testimony | Q3 2026 |
| First bellwether trial | Late 2026 to Q1 2027 |
| Initial settlement negotiations | Q1-Q2 2027 |
| Global settlement framework | Mid to late 2027 |
| First settlement payments | Late 2027 to 2028 |
This timeline is aggressive compared to most pharmaceutical MDLs. But Judge Pratter has shown a willingness to push both sides forward.
If Daubert hearings go poorly for plaintiffs and key experts are excluded, the timeline could shift significantly. Novo Nordisk would have less incentive to settle, and the litigation could drag on.
On the other hand, if Daubert hearings go well and bellwether trials produce strong plaintiff verdicts, a settlement could come together faster than expected. The Bayer Roundup settlement, for example, reached a $10.9 billion agreement within months of devastating trial losses for the defense.
Every big pharmaceutical mass tort follows a similar pattern: fight, test, settle. We're in the "test" phase now.
Key Takeaway: Most legal experts expect the first Ozempic settlement payments to begin in late 2027 or 2028, but the groundwork being laid in 2026 will determine how large and how fast those payments come.
Ozempic Lawsuit Eligibility: Do You Meet the Criteria?
Ozempic lawsuit eligibility comes down to three core factors: you took the drug, you were harmed, and your harm was not adequately warned about. Meeting all three gives you the strongest possible claim.
Here's a detailed eligibility checklist:
You likely qualify if:
- You were prescribed semaglutide (Ozempic, Wegovy, or Rybelsus)
- You used the drug for a minimum of several weeks
- You developed one or more of the following conditions:
- Gastroparesis
- Bowel obstruction or ileus
- Pancreatitis
- Gallbladder disease or gallbladder removal
- Cyclic vomiting syndrome
- Severe, prolonged nausea requiring medical intervention
- You have medical records documenting the diagnosis
- Your condition was diagnosed while taking the drug or within months of stopping
You may not qualify if:
- You only experienced mild, short-term nausea that resolved on its own
- You had a pre-existing gastroparesis diagnosis before starting semaglutide
- You cannot obtain medical records supporting your claim
- Your statute of limitations has already expired
The gray area involves patients who had minor pre-existing GI issues that were dramatically worsened by Ozempic. Those cases can still be viable, but they require stronger medical evidence showing the drug caused the escalation.
An attorney can evaluate your specific situation during a free case review. Don't self-diagnose your eligibility. Let a professional look at the facts.
Ozempic Lawsuit Updates: Key Dates to Watch
Several key dates in 2026 will shape the trajectory of the Ozempic lawsuit. Keeping track of these milestones helps you understand where your case stands and what comes next.
Critical dates and deadlines for 2026:
- Q1 2026: Bellwether case pool narrowed to final candidates. Both sides submit case selection briefs.
- Q2 2026: Plaintiffs' expert witness reports on causation and damages due. Novo Nordisk's rebuttal experts follow.
- Q3 2026: Daubert hearing motions filed and argued. The court decides which expert testimony is admissible at trial.
- Q4 2026: Pretrial motions, jury instructions, and trial scheduling for first bellwether case. Possible first trial date set.
- Ongoing throughout 2026: New cases continue to be filed and transferred into the MDL. Discovery remains open for newer claims.
State court cases in California and New Jersey may reach trial before the federal MDL. If a state jury delivers a significant verdict first, it could accelerate federal settlement talks.
The Daubert hearing in Q3 is arguably the single most important event of 2026. If plaintiffs' experts survive Daubert, the path to trial is clear. If they don't, the litigation faces a serious setback.
Both sides have retained top-tier expert witnesses. Plaintiffs are relying on gastroenterologists, pharmacologists, and epidemiologists. Novo Nordisk has its own team of medical experts prepared to counter the causation argument.
Ozempic Lawsuit News: What Experts Are Saying
Legal experts and mass tort analysts are closely watching the Ozempic lawsuit as one of the most significant pharmaceutical cases of the decade. The consensus among plaintiff-side attorneys is cautiously optimistic heading into 2026.
Here's what different voices are saying:
Plaintiff attorneys believe the evidence is strong. Internal Novo Nordisk documents obtained during discovery reportedly show the company tracked gastroparesis adverse events for years before updating its drug label. That's the kind of evidence that resonates with juries.
Defense-side analysts point out that semaglutide's label has always mentioned GI side effects, including nausea and vomiting. Novo Nordisk argues that gastroparesis is a known pharmacological effect of GLP-1 drugs and was not hidden.
Medical researchers have published new studies in 2025 and early 2026 showing that semaglutide-induced gastroparesis can persist long after patients stop taking the drug. One study found that 40% of patients with semaglutide-related gastroparesis still had symptoms six months after discontinuation.
FDA watchers note that the agency has required multiple label updates for semaglutide products since 2023. Each update adds to the argument that the original warnings were insufficient.
The financial stakes are enormous. Ozempic generated $18.4 billion in global sales for Novo Nordisk in 2024 alone. Wegovy added another $8.3 billion. A mass settlement could easily reach into the billions, though the exact figure depends on trial outcomes.
This isn't a small-stakes case. It's a confrontation between one of the world's most profitable drugs and thousands of people who say it ruined their health.
Key Takeaway: Expert opinion in 2026 is split but leans toward plaintiffs, with newly published medical research and FDA label changes bolstering the argument that Novo Nordisk failed to adequately warn patients about the true risks of semaglutide.
Frequently Asked Questions
How much money can I get from the Ozempic lawsuit in 2026?
Most estimates place individual payouts between $25,000 and $500,000 or more depending on injury severity.
Fatal cases and those involving permanent gastroparesis or major surgery could exceed $1 million.
No payments are expected until late 2027 at the earliest, after bellwether trials set a framework for settlement.
What is the deadline to file an Ozempic lawsuit in 2026?
The deadline depends on your state's statute of limitations, which ranges from 2 to 3 years from discovery of injury.
If you were diagnosed with a qualifying injury in 2024, your deadline could fall in 2026 or 2027.
Filing sooner protects your rights and gives your attorney more time to build a strong case.
Does gastroparesis qualify me for the Ozempic lawsuit?
Yes, gastroparesis is the primary injury alleged in the Ozempic lawsuit.
You need medical records confirming the diagnosis and evidence that you were taking semaglutide when symptoms developed.
Cases involving hospitalization or surgery for gastroparesis are considered the strongest.
Is the Ozempic lawsuit a class action or mass tort?
The Ozempic lawsuit is a mass tort handled through MDL No. 3094, not a class action.
Each plaintiff's case is evaluated individually based on their specific injuries and evidence.
This structure means payouts vary by person rather than being split equally among all claimants.
When will Ozempic lawsuit settlements be paid out?
The earliest settlement payments are expected in late 2027 or 2028.
Global settlement negotiations will likely begin after the first bellwether trial produces a verdict.
The timeline depends on Daubert hearing outcomes, trial results, and Novo Nordisk's willingness to negotiate.
What to Do Next
The Ozempic lawsuit in 2026 is entering its most critical phase. Bellwether trials, Daubert hearings, and settlement negotiations will all take shape this year.
If you took Ozempic or a related GLP-1 drug and suffered serious side effects, now is the time to act. Get your medical records together. Talk to a mass tort attorney. Protect your filing deadline.
This case is moving. Don't get left behind.
